Standardized Ki67 diagnostics using automated scoring - Clinical validation in the GeparTrio breast cancer study

Clinical Cancer Research

Volumn 21, Issue 16, 2015, Pages 3651-3657

  Klauschen, Frederick ^a   Wienert, Stephan ^a,b   Schmitt, Wolfgang D ^a   Loibl, Sibylle ^c   Gerber, Bernd ^d   Blohmer, Jens Uwe ^a   Huober, Jens ^e   Rüdiger, Thomas ^f   Erbstößer, Erhard ^g   Mehta, Keyur ^c   Lederer, Bianca ^c   Dietel, Manfred ^a   Denkert, Carsten ^a   Von Minckwitz, Gunter ^c,h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VMSCOPE GMBH   (Germany)

^c GERMAN BREAST GROUP   (Germany)

^d University Women's Hospital   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Klinikum Karlsruhe   (Germany)

^g AMEOS Klinikum Halberstadt   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; KI 67 ANTIGEN; NAVELBINE; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ARTICLE; AUTOMATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCORING SYSTEM; STANDARDIZATION; TREATMENT RESPONSE; VALIDATION PROCESS; ADULT; AGED; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; TAXOIDS;

EID: 84940463741     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1283     Document Type: Article

References (25)

1. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
2. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96: 1504-13.
3. Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24: 2786-93.
4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.
5. Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915.
6. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17: 323-34.
7. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-20.
8. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-83.
9. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-906.
10. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE 2012; 7: e37379.
11. Cass JD, Varma S, Day AG, Sangrar W, Rajput AB, Raptis LH, et al. Automated quantitative analysis of p53, cyclin D1, Ki67 and pERK expression in breast carcinoma does not differ from expert pathologist scoring and correlates with clinico-pathological characteristics. Cancers 2012; 4: 725-42.
12. Konsti J, Lundin M, Joensuu H, Lehtimaki T, Sihto H, Holli K, et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 2011; 11: 3.
13. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012; 106: 383-8.
14. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52.
15. Wienert S, Heim D, Kotani M, Lindequist B, Stenzinger A, Ishii M, et al. Cognition Master: an object-based image analysis framework. Diagn Pathol 2013; 8: 34.
16. Wienert S, Heim D, Saeger K, Stenzinger A, Beil M, Hufnagl P, et al. Detection and segmentation of cell nuclei in virtual microscopy images: a minimum-model approach. Sci Rep 2012; 2: 503.
17. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-51.
18. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-62.
19. Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man, Cybern 1979; 9: 62-6.
20. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23: 291-9.
21. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7: e51862.
22. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-29.
23. von Minckwitz G, Schmitt WD, Loibl S, Muller BM, Blohmer JU, Sinn BV, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19: 4521-31.
24. Krecsak L, Micsik T, Kiszler G, Krenacs T, Szabo D, Jonas V, et al. Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer. Diagn Pathol 2011; 6: 6.
25. Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 2012; 7: 27.